Selective spectrum antibiotic modulation of the gut microbiome in obesity and diabetes rodent models

Abstract

The gastrointestinal tractmicrobiome has been suggested as a potential therapeutic target for metabolic diseases such as obesity and Type 2 diabetes mellitus (T2DM). However, the relationship between changes in microbial communities and metabolic disease-phenotypes are still poorly understood. In this study, we used antibiotics with markedly different antibacterial spectra to modulate the gut microbiome in a diet-induced obesity mousemodel and thenmeasured relevant biochemical, hormonal and phenotypic biomarkers of obesity and T2DM.Mice fed a high-fat diet were treated with either ceftazidime (a primarily anti-Gramnegative bacteria antibiotic) or vancomycin (mainly anti-Gram positive bacteria activity) in an escalating threedose regimen.We also dosed animals with a well-known prebiotic weight-loss supplement, 10%oligofructose saccharide (10%OFS). Vancomycin treated mice showed little weight change and no improvement in glycemic control while ceftazidime and 10% OFS treatments induced significant weight loss. However, only ceftazidime showed significant, dose dependent improvement in keymetabolic variables including glucose, insulin, protein tyrosine tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Subsequently, we confirmed the positive hyperglycemic control effects of ceftazidime in the Zucker diabetic fatty (ZDF) rat model. Metagenomic DNA sequencing of bacterial 16S rRNA gene regions V1-V3 showed that the microbiomes of ceftazidime dosed mice and rats were enriched for the phylum Firmicutes while 10% OFS treated mice had a greater abundance of Bacteroidetes.We show that specific changes inmicrobial community composition are associated with obesity and glycemic control phenotypes. More broadly, our study suggests that in vivo modulation of the microbiome warrants further investigation as a potential therapeutic strategy for metabolic diseases.